Figure 4.

Effect of T Cell Depletion on ppp dsRNA LCP-AEAA Therapy

(A) KPC-RFP/Luc tumor-bearing mice were treated with ppp dsRNA LCP-AEAA intravenously. Mice were pre-treated with anti-CD8 and anti-CD4 antibodies intraperitoneally 1 day before administration of the ppp dsRNA LCP-AEAA nanoparticles. Tumor growth was monitored, and fold change was quantified by bioluminescence imaging. (B) Mice were sacrificed on day 29 after inoculation at the end of the study, and pancreatic tumor weights were compared between the treatment groups (n = 3–4). (C) Post-treatment, KPC-RFP/Luc tumor-bearing mice from intervention groups (n = 3) were sacrificed (day 29). Tumor tissues were harvested, and single-cell suspensions were stained and analyzed by flow cytometry.